Halozyme Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | $199.2M | $-32.5M | $66.8M |
| FY2017 | $125.1M | $208.4M | $168.7M |
| FY2018 | $34.9M | $248.9M | $57.9M |
| FY2019 | $383.0M | $91.8M | $120.2M |
| FY2020 | $0 | $151.0M | $147.7M |
| FY2021 | $787.3M | $197.0M | $118.7M |
| FY2022 | $1.49B | $169.8M | $234.2M |
| FY2023 | $1.50B | $83.8M | $118.4M |
| FY2024 | $1.51B | $363.8M | $115.9M |
| FY2025 | $2.14B | $48.8M | $133.8M |